NCT03090659: Phase 1/2 - A Chinese study of LCAR-B38M CAR-T cells in RRMM -Myeloma (LEGEND-2)
Updated: Sep 2
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).
LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)
A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients
LCAR-B38M CAR-T cell injection
Nanjing Legend Biotech Co.
Second Affiliated Hospital of Xi'an Jiaotong University
Jiangsu Provincial People's Hospital
Shanghai Changzheng Hospital
ClinicalTrials.gov Identifier: NCT03090659
J Hematol Oncol; Dec. 2018
CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate
Asco Post July, 2017
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
Meeting Abstract, ASCO 2017